Breaking News Instant updates and real-time market news.

CALA

Calithera Biosciences

$3.35

-0.05 (-1.47%)

18:05
11/29/16
11/29
18:05
11/29/16
18:05

Calithera Biosciences reports Phase 1 data on kidney cancer treatment

Calithera Biosciences announced that clinical data from its lead product candidate CB-839, a first-in-class glutaminase inhibitor, will be presented at the EORTC-NCI-AACR Symposium. "The data demonstrate the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with renal cell carcinoma," the company noted, adding that "we are pleased to present combination data of CB-839 with everolimus that demonstrates high rates of disease control with a well-tolerated combination therapy." On the specific Phase 1 data to be presented, Calithera noted: "As of October 25, 15 renal cell carcinoma patients were treated and evaluable for response, including 12 clear cell patients, and three papillary patients. Ninety-three percent have disease control; one patient has a partial response, one patient has progressive disease, and 13 patients have stable disease. The median progression free survival is 8.5 months and for the majority of patients, their time on therapy is longer than their time on treatment in their prior therapy. In the clear cell patient population the disease control rate is 100% and eight patients remain on study. For comparison, in a separate trial of everolimus vs. cabozantinib, the progression free survival of patients in the everolimus group from the Meteor Phase 3 study in second and third line patients was 3.9 months... The addition of CB-839 to full dose everolimus has been well tolerated, with a similar safety profile to the known profile of everolimus alone. Grade 3 events include two events of hyperglycemia and one event each of diarrhea, anemia and fatigue." The company said that, on the basis of this efficacy and safety data, it plans to continue development in combination therapy for clear cell renal cell carcinoma.

CALA Calithera Biosciences
$3.35

-0.05 (-1.47%)

10/25/16
SBSH
10/25/16
INITIATION
Target $1
SBSH
Sell
Calithera Biosciences initiated with a Sell at Citi
Citi analyst Robyn Karnauskas started Calithera Biosciences with a Sell rating and $1 price target. The company is targeting cancer metabolism but it could take a long time before meaningful data is seen, Karnauskas tells investors in a research note. The analyst sees a lack of potentially stock moving catalysts.

TODAY'S FREE FLY STORIES

AZO

AutoZone

$535.19

-28.21 (-5.01%)

07:18
09/20/17
09/20
07:18
09/20/17
07:18
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 30

    Oct

RGNX

Regenxbio

$29.05

-0.75 (-2.52%)

07:18
09/20/17
09/20
07:18
09/20/17
07:18
Hot Stocks
Regenxbio completes dosing of first cohort in Phase I clinical trial of RGX-314 »

Regenxbio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

, BABA

Alibaba

$180.07

0.09 (0.05%)

07:17
09/20/17
09/20
07:17
09/20/17
07:17
Periodicals
Amazon takes on rivals in India digital payments market, The Information says »

Amazon (AMZN) has taken…

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

BABA

Alibaba

$180.07

0.09 (0.05%)

SFTBF

SoftBank

$82.75

4.45 (5.68%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

SBNY

Signature Bank

$120.15

0.21 (0.18%)

07:16
09/20/17
09/20
07:16
09/20/17
07:16
Downgrade
Signature Bank rating change  »

Signature Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HK

Halcon Resources

$6.23

-0.19 (-2.96%)

07:14
09/20/17
09/20
07:14
09/20/17
07:14
Hot Stocks
Halcon Resources announces sale of non-operated Williston Basin assets »

Halcon Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

07:14
09/20/17
09/20
07:14
09/20/17
07:14
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.49

-0.03 (-0.09%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Conference/Events
Cisco management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 22

    Oct

  • 15

    Nov

AVEO

AVEO Oncology

$3.84

0.07 (1.86%)

, BMY

Bristol-Myers

$62.93

0.23 (0.37%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Hot Stocks
AVEO Oncology, EUSA Pharma announce TiNivo combination study opt-in »

AVEO Oncology (AVEO) and…

AVEO

AVEO Oncology

$3.84

0.07 (1.86%)

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

ADBE

Adobe

$156.60

0.83 (0.53%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SUPN

Supernus

$38.05

-11.6 (-23.36%)

07:11
09/20/17
09/20
07:11
09/20/17
07:11
Recommendations
Supernus analyst commentary  »

Jefferies still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WFC

Wells Fargo

$53.36

0.65 (1.23%)

07:10
09/20/17
09/20
07:10
09/20/17
07:10
Periodicals
Wells Fargo general counsel aims to clean up reputation, Reuters reports »

Wells Fargo general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

ELY

Callaway Golf

$14.14

0.12 (0.86%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Callaway Golf analyst commentary  »

Callaway Golf EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$252.46

-0.62 (-0.24%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MTCH

Match Group

$23.45

-0.02 (-0.09%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Recommendations
Match Group analyst commentary  »

Match Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Hot Stocks
Breaking Hot Stocks news story on General Mills »

General Mills down 4.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

KPTI

Karyopharm

$10.52

-0.34 (-3.13%)

07:07
09/20/17
09/20
07:07
09/20/17
07:07
Hot Stocks
Karyopharm: 'successful' outcome from Phase 2 portion of Phase 2/3 SEAL study »

Karyopharm reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
General Mills CEO says FY18 priority is 'strengthening our topline performance' »

"Our number one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SNY

Sanofi

$49.10

0.46 (0.95%)

, ALNY

Alnylam

$75.04

-0.96 (-1.26%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
Sanofi and Alnylam report topline results of patisiran in ATTR amyloidosis »

Sanofi's (SNY)…

SNY

Sanofi

$49.10

0.46 (0.95%)

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ADBE

Adobe

$156.60

0.83 (0.53%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Recommendations
Adobe analyst commentary  »

Adobe near-term weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

WDC

Western Digital

$89.92

0.74 (0.83%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Technical Analysis
Technical View: Western Digital falls as Toshiba selects Bain-led group as buyer »

Toshiba (TOSBF, TOSYY)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Hot Stocks
General Mills CEO says 'confident in improved momentum' for rest of year »

CEO Harmening said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SIX

Six Flags

$56.75

-0.32 (-0.56%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Six Flags says no expected material impact from Mexico earthquake »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

PG

Procter & Gamble

$94.17

1.02 (1.10%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Procter & Gamble: Peltz 'lacks specific qualities' P&G seeking in board members »

The Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
General Mills reports Q1 gross margin down 150 bps to 34.8% »

Gross margin decreased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

07:02
09/20/17
09/20
07:02
09/20/17
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 9/15 MBA Mortgage…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.